What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

01/02/2017

First sale and implant in Germany following CE Marking

Dublin – Ireland, 1 February 2017 – Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), announces the first sale and implant of ReActiv8 in Germany.
The ReActiv8 implant was performed by Dr. med. Francis Kilian, Orthopedic and Neurosurgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz Germany.
Dr. Kilian commented: “As spine surgeons we are always looking to address the underlying cause of a patient’s condition but until now we had no effective option to offer to patients with Chronic Low Back Pain due to impaired control of their back muscles. ReActiv8 represents a significant breakthrough for this large group of patients who are not candidates for spine surgery and fills an important void in our restorative treatment portfolio.”
ReActiv8 works by electrically stimulating the nerves responsible for contracting the key stabilizing muscles of the lumbar spine. Activation of these muscles to restore functional spine stability has been shown to facilitate recovery from CLBP.
Peter Crosby, CEO of Mainstay, commented: “The first sale and implant of ReActiv8 in Germany is an important milestone for Mainstay. We are fully committed to working with our customers to integrate ReActiv8 into their routine clinical practice and provide a new option for many people suffering from chronic low back pain.”
Mainstay’s European commercial activities for ReActiv8 are initially focused on Germany where the Company aims to drive adoption of ReActiv8 in a select number of high volume multi-disciplinary spine care centers. As the Company gains experience and momentum, it will expand to other sites and countries.
Mainstay received CE Marking for ReActiv8 supported by positive results from the ReActiv8-A Clinical Trial that demonstrated a clinically important, statistically significant and lasting improvement in pain, disability and quality of life in people with disabling CLBP and few other treatment options.

About Mainstay
Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain
One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.
Further information can be found at www.mainstay-medical.com

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys
Tel: +44 203 709 5700 / +44 7921 697 654
Email: mainstaymedical@consilium-comms.com

FTI Consulting (for Ireland)
Jonathan Neilan Tel: +353 1 663 3686
Email: jonathan.neilan@fticonsulting.com

NewCap (for France)
Julie Coulot
Tel: +33 1 44 71 20 40
Email: jcoulot@newcap.fr

AndreasBohne.Com/Kötting Consulting (for Germany)
Andreas Bohne
Tel : +49 2102 1485368
Email : abo@andreasbohne.com
Wilhelm Kötting
Tel: +49 69 75913293
Email: wkotting@gmail.com

Investor Relations:
LifeSci Advisors, LLC
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com

ESM Advisers:
Davy
Fergal Meegan or Barry Murphy
Tel: +353 1 679 6363
Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie
Forward looking statements
This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should”, “will”, or “explore” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory applications and approvals, reimbursement arrangements, costs of sales and market penetration.
By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company’s operations, and the development of its main product, the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company’s results of operations, financial position and growth, and the development of its main product and the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, the successful launch and commercialisation of ReActiv8, the progress and success of the ReActiv8-B Clinical Trial, general economic and business conditions, the global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, the time required to commence and complete clinical trials, the time and process required to obtain regulatory approvals, currency fluctuations, changes in its business strategy, political and economic uncertainty. The forward-looking statements herein speak only at the date of this announcement.

26/01/2017

Paris, France, 26 janvier. 2017. Sofinnova Partners, un des leaders du capital risque en Europe spécialisé dans les sciences de la vie, annonce la cession de Delinia, une société spécialisée dans le traitement des maladies auto-immunes graves, à Celgene Corporation (NASDAQ: CELG), pour une valeur totale pouvant aller jusqu’à 775 M$, avec un paiement initial de 300 M$ et un paiement additionnel conditionné à la réalisation de certaines étapes de développement, en lien avec son produit phare DEL-106.

Depuis le financement d’amorçage jusqu’à la cession, Sofinnova Partners a constamment soutenu le développement de Delinia, et jusqu’à l’accord d’aujourd’hui en était l’actionnaire majoritaire, à part égale avec Atlas Venture. Delinia développe des thérapies qui visent à rééquilibrer le système immunitaire pour le traitement de maladies auto-immunes graves et mortelles. Son produit phare, DEL-106, active de façon sélective les lymphocytes T régulateurs (Treg) dans le but de traiter les dérèglements immunitaires sans pour autant altérer largement le système immunitaire du patient. La plateforme thérapeutique de Delinia repose sur une technologie créée par le co-fondateur et Directeur scientifique, Jeffrey Greve PhD. L’approche de Delinia consiste à rétablir une régulation immunitaire normale plutôt que d’altérer le système immunitaire. Créée en 2014, Delinia est basée à Cambridge (Massachusetts, Etats Unis) avec des activités de R&D à San Francisco (Californie, Etats Unis).

Celgene Corporation est une entreprise biopharmaceutique qui développe et commercialise des thérapies innovantes reposant sur la régulation de protéines et de gènes dans le domaine des cancers et des maladies inflammatoires.

Henrijette Richter, Partner de Sofinnova Partners et membre du Conseil d’administration de Delinia déclare : “le succès de Delinia illustre parfaitement notre stratégie qui consiste à identifier des entrepreneurs remarquables et les aider à bâtir des entreprises exceptionnelles. Nous sommes ravis de cet accord, et au regard de l’engagement fort de Celgene en faveur de l’innovation médicale, c’était le partenaire idéal pour accélérer le développement de DEL-106 dans le but d’apporter au marché et aux millions de patients concernés des solutions thérapeutiques meilleures”.

Cet accord est soumis à certaines conditions réglementaires, notamment la fin du délai d’attente prévu par le Hart-Scott-Rodino Antitrust Improvements Act of 1976. L’accord définitif devrait intervenir dans le courant du premier trimestre 2017.

POUR PLUS D’INFORMATION, VEUILLEZ CONTACTER :

SOFINNOVA PARTNERS
Anne REIN
+33 6 03 35 92 05
anne.rein@strategiesimage.com
A propos de Sofinnova Partners
Sofinnova Partners est un des leaders du capital risque en Europe spécialisé dans les sciences de la vie. Basée à Paris, l’équipe est composée de 12 professionnels de l’investissement issus d’Europe, des Etats Unis et de Chine. La société investit dans les technologies de changement de paradigme aux côtés d’entrepreneurs visionnaires. Sofinnova Partners intervient en priorité dans les start up et spin-off d’entreprises en tant qu’investisseur fondateur et chef de file. Depuis plus de 40 ans, la société a accompagné plus de 500 entreprises à travers le monde devenues des leaders sur leur marché. Sofinnova Partners gère aujourd’hui 1,5 milliard d’euros.
Pour plus d’information : www.sofinnova.fr

26/01/2017
25/01/2017

Geneva, Switzerland – January 25, 2017 – ObsEva SA (ObsEva) announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva’s common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol “OBSV” on January 26, 2017.

Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the proposed offering.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on January 25, 2017. This offering is being made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus, when available, may be obtained for free by visiting the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus and the final prospectus, when available, may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at 1-800-221-1037, or by email at newyork.prospectus@credit-suisse.com; from Jefferies LLC, Attention: Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by emailing Prospectus_Department@Jefferies.com, or by calling 1-877-821-7388; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at syndicate@leerink.com, or by calling 1-800-808-7525 ex. 6142.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ObsEva SA
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical-stage pipeline with multiple development programs focused on treating the symptoms associated with uterine fibroids and endometriosis, improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization, and treating preterm labor.
MEDIA CONTACT
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526

COMPANY CONTACT
Delphine Renaud
ObsEva, CEO Office
delphine.renaud@obseva.ch

23/01/2017

Paris, January the 18th, 2017. DNA Script announced today it welcomed Dr. Heiner Dreismann to its board of directors.

Dr. Dreismann, 63, is recognized as a driving force behind the adoption of the polymerase chain reaction (PCR) technique in the 1990s for use in basic research and drug discovery laboratories. PCR technology revolutionized molecular biology allowing researchers to amplify a few copies of a piece of DNA across several orders of magnitude. The technique continues to be important to researchers today, especially in the areas of biotechnology and genetics. While CEO of Roche Molecular Diagnostics, Dr. Dreismann led the development and commercialization of an expansive portfolio of PCR products, sustaining Roche’s industry leadership in Molecular Diagnostics.

« Heiner guided the world leader in molecular diagnostics and tools, and we are very proud that he is willing to share his experience and help us accelerate our growth, » said Thomas Ybert, chief executive officer of DNA Script. « We look forward to his contribution to our strategic development plan and rapid commercialization of our unique technology. »

Dr. Dreismann added, « I believe that DNA Script’s technology has the potential to radically transform the genetic engineering industry with a novel enzymatic approach to DNA synthesis, similar to what PCR did in the nineties. It is a privilege to join this exciting and dynamic team, and I look forward to working closely with the management and the board members during the next stages of DNA Script’s growth. »

About DNA Script
DNA Script is a Paris-based company focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script leverages nature’s billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

Its technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. DNA Script develops its technology in partnership with Institut Pasteur and Institut Pierre Gilles de Gennes with the support of key investors such as Sofinnova Partners, Kurma Partners and Idinvest Partners.

www.dnascript.co

Contact
Sylvain Gariel, COO
sg@dnascript.co
+33.6.28.04.53.11
www.dnascript.co

19/01/2017

Toulouse, FRANCE, Ann Arbor, UNITED STATES January 19, 2017– Cerenis Therapeutics (Euronext: CEREN- ISIN: FR0012616852), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, updates on its clinical advancements and announces its cash position at December 31, 2016 as well as its revenue for the fourth quarter 2016.
Please find attached the full PDF file related to this information.

About CER-209
CER-209 is the first drug candidate in the category of oral P2Y13 receptor agonists. The P2Y13 receptor is a member of the P2Y receptor family, a well-known receptor family including the P2Y12 receptor that is the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®). CER-209 is a specific agonist of the P2Y13 receptor and does not interact with the P2Y12 receptor. In preclinical studies CER-209 promotes HDL recognition by the liver and increases Reverse Lipid Transport (RLT), thereby impacting atherosclerosis regression. Because of the favorable metabolic effects observed in the liver, CER-209 may also offer a new mechanism for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

About CER-001
CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. Previous Phase II studies have provided important data demonstrating the efficacy of CER-001 in regressing atherosclerosis in several distinct vascular beds in patients representing the entire spectrum of cholesterol homeostasis. The totality of the data to date indicates that CER-001 performs all of the functions of natural pre-beta HDL particles and has the potential to be the best-in-class HDL mimetic in the market.
About Cerenis Therapeutics: www.cerenis.com
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.

Since its inception in 2005, the Company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.

●●●
CONTACTS
Cerenis
CEO
Jean-Louis Dasseux
Tel: +33 (0)5 62 24 09 49
info@cerenis.com

NewCap
Investor relations
Emmanuel Huynh / Louis-Victor Delouvrier
Media relations
Nicolas Merigeau
Tel: +33 (0)1 44 71 98 53
cerenis@newcap.eu

17/01/2017

Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman’s reproductive health and pregnancy, announced today the appointment of a new Chief Financial Officer, Timothy M. Adams. Mr. Adams is located in Boston, Massachusetts, where the Company is currently hiring finance, IR and clinical operation people to support ObsEva’s clinical-stage programs in uterine fibroids, endometriosis, Assisted Reproductive Technology and preterm labor.
Mr. Adams has over 30 years of industry experience and most recently served as Executive Vice President and Chief Financial Officer of Demandware, Inc., an enterprise cloud commerce solutions company acquired by Salesforce in 2016. Previously, Mr. Adams served as Senior Vice President and Chief Financial Officer of athenahealth, Inc., Chief Investment Officer of Constitution Medical Investors and Chief Financial Officer at a number of publicly traded companies including Cytyc Corporation, a market leader in women’s health diagnostic and device products and Digex, Inc.
ObsEva is also pleased to announce that Frank Verwiel, M.D., who has served on the company’s Board of Directors since early 2016, has been elected Chairperson of the Board. Dr. Verwiel has over 25 years of experience across multiple operational, development and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Prior to joining the ObsEva Board, he was President and Chief Executive Officer of Aptalis Pharma. He is currently a member of the Board of Directors of AveXis, Inc., Achillion Pharma, Inc. and Bavarian Nordic A/S. Dr. Verwiel succeeds Annette Clancy, BSc, who has served as the Chairperson of the Board since ObsEva’s inception and who we are pleased to announce will continue to serve as a non-executive Board member and Chair of Compensation Committee.
Additionally, Barbara Duncan, formerly of Intercept Pharmaceuticals, Inc., has joined ObsEva’s Board of Directors as the Chair of the Audit Committee. Ms. Duncan has 20 years of financial management experience in the industry and was previously the Chief Financial Officer and Treasurer at Intercept Pharmaceuticals Inc., Chief Executive Officer and Treasurer at DOV Pharmaceuticals, Inc., and Vice President at Lehman Brothers, Inc. She currently sits on the Board of Directors of publicly traded companies Adaptimmune Therapeutics plc, Aevi Genomic Medicine, Inc. and Innoviva, Inc.
“We are very excited to be welcoming Tim to ObsEva as we expand our reach into the United States,” said Ernest Loumaye, M.D., Ph.D., ObsEva’s CEO and Co-Founder. “As we enter this new chapter for the company the addition of Frank’s and Barbara’s leadership and knowledge on our Board of Directors are invaluable to the company’s strategy of driving forward the development of potential novel, best-in-class women’s reproductive health and pregnancy therapeutics.”

About ObsEva
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 15 and 49, millions of women worldwide suffer from reproductive health conditions that affect their quality of life or their ability to conceive and may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical-stage pipeline with multiple development programs focused on treating the symptoms associated with uterine fibroids and endometriosis, improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization, and treating preterm labor. For more information, please visit www.ObsEva.com.

MEDIA CONTACT
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
COMPANY CONTACT
Delphine Renaud
ObsEva, CEO Office
delphine.renaud@obseva.ch
+41 22 552 1550

13/01/2017

• Completion of the commercial reorganization
• Recomposition of the Board of Directors
• Solid cash position of €17 million at December 31, 2016

PARIS – January 12, 2017 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® coronary stent, today announces its revenues for the fourth quarter and full year 2016.
2016 annual and fourth-quarter revenues*
Over the fourth quarter of 2016, STENTYS recorded revenues of almost €2.0 million, an increase of +5% compared with the fourth quarter of 2015. This limited growth rate was notably due to the commercial reorganization undertaken during the second half of 2016 in order to benefit from a more operational structure in 2017.
Over 2016 as a whole, revenues were up +20%, at €7.3 million.
Solid cash position of €17 million as a result of the €12.6 million rights issue and cost reductions
At December 31, 2016, STENTYS had a cash position of €17 million, versus €10.7 million at December 31, 2015, due firstly to the rights issue carried out in February 2016 and secondly to the cost reductions achieved over the second half of the year thanks to the reorganization of certain operational functions initiated in July.
Recomposition of the Board of Directors
On the initiative of the Chairman of the Board of Directors, and within the context of the refocusing of STENTYS’ activities on high-potential markets in Europe, the Middle East, Asia and Latin America, the Company’s two North American Directors, Mrs. Dianne Blanco and Mr. Michael Lesh, have stood down from the Board.
Christophe Lottin, Chief Executive Officer, comments: “We recorded annual growth of 20% in 2016, while reorganizing STENTYS’ operational and commercial functions in the fourth quarter in order to better meet market expectations and maintain our cash position. In 2017, our ambition will be to accelerate our growth by maximizing the adoption of our stents by cardiologists in Europe and high-potential countries while continuing to control our operating costs.”
Upcoming financial publication
STENTYS expects to publish its 2016 annual results on Wednesday March 22, 2017

* Figures reviewed by the statutory auditors

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America. More information is available at www.stentys.com.
Safe Harbor Statements
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2015 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on August 30, 2016 under number D.16-804.

STENTYS
Christophe Lottin
CEO
Tel.: +33 (0)1 44 53 99 42
invstor@stentys.com
NewCap
Investor Relations / Strategic Communications
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.eu

STENTYS is listed on Comp. C of the Euronext Paris market
ISIN: FR0010949404 – Ticker: STNT

11/01/2017

Pixium Vision, société qui développe et commercialise des systèmes de vision bionique innovants en vue de permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce avoir finalisé l’implantation de 10 systèmes IRIS®II dans le cadre de son étude clinique. Tous les patients implantés vont désormais suivre le programme de rééducation tel que prévu dans l’étude européenne multicentrique en cours IRIS® II, démarrée en janvier 2016.
Khalid Ishaque, Directeur Général de Pixium Vision, commente : «L’achèvement du recrutement démontre le grand intérêt pour notre système innovant de vision bionique IRIS®II. Au sein de la communauté ophtalmologique et de la vision bionique, de nombreuses personnes attendent les résultats intermédiaires prévus courant 2017, qui seront importants pour le développement des systèmes d’implants rétiniens de Pixium Vision. La société est engagée dans la conception, le développement et la mise à disposition, auprès des chirurgiens, d’innovations significatives en vision bionique, qui leur permettront de traiter des patients qui ont perdu la vue suite à des dystrophies rétiniennes.»

À PROPOS D’IRIS®II
IRIS®II est un système de vision bionique doté d’une caméra bio-inspirée et d’un implant épi-rétinien de 150 électrodes, conçu pour être explantable et, à terme, évolutif, pour les patients qui ont perdu la vue suite à une Rétinite Pigmentaire (RP).
Pixium Vision a reçu le marquage CE pour IRIS®II en Juillet 2016, lui permettant de lancer ses activités commerciales, sujettes aux disponibilités de remboursement. L’obtention du marquage CE permet à la Société de déposer ses demandes de remboursement national pour IRIS®II. La Société travaille dans un premier temps avec les autorités publiques dans le cadre du remboursement des technologies innovantes pour les dispositifs médicaux, en France avec le Forfait Innovation, et en Allemagne avec le NUB.
À PROPOS DE L’ETUDE CLINIQUE
L’étude clinique référencée NCTC02670980 (https://www.clinicaltrials.gov) évalue les performances et la sécurité d’IRIS®II sur 10 patients souffrant de Rétinite Pigmentaire, du syndrome de Usher, de dystrophie des cônes et des bâtonnets, ou encore de Choroïdérémie. Chaque patient est suivi sur une période minimale de 18 mois, avec 18 mois supplémentaires si le patient choisit de prolonger l’étude.
L’essai clinique, démarré en janvier 2016, est une étude européenne multicentrique et prospective, ouverte et non randomisée, visant à démontrer l’efficacité du système de vision bionique IRIS®II comme traitement pour compenser la cécité et potentiellement fournir des perceptions visuelles aux personnes aveugles pour leur rendre une plus grande autonomie et une meilleure qualité de vie. L’étude est menée dans des centres ophtalmologiques prestigieux en France, au Royaume-Uni, en Espagne, en Autriche et en Allemagne. http://www.pixium-vision.com/fr/essai_clinique/participating-centers

À PROPOS DE PIXIUM VISION
La mission de Pixium Vision est de créer un monde de vision bionique, pour permettre aux personnes ayant perdu la vue de vivre de façon plus autonome. Les systèmes de Pixium Vision sont composés de plusieurs éléments de haute technologie associés à une intervention chirurgicale et à une période de rééducation.
La société développe deux systèmes de vision bionique. IRIS®II, le premier système a obtenu le marquage CE en juillet 2016. En parallèle, Pixium Vision a récemment finalisé les phases d’études pré-cliniques de PRIMA, un implant photovoltaïque sous-rétinien miniaturisé et sans fil, et prévoit de démarrer les premiers essais cliniques chez l’Homme.
Pixium Vision travaille en étroite collaboration avec des partenaires académiques de renommée mondiale tels que l’Institut de la Vision à Paris et le Laboratoire de physique expérimentale Hansen à l’Université Stanford et le Moorfields Eye Hospital de Londres. La société est certifiée EN ISO 13485.

Pour plus d’informations : http://www.pixium-vision.com/fr
Suivez-nous sur Twitter: @PixiumVision; Facebook: www.facebook.com/pixiumvision
LinkedIn: www.linkedin.com/company/pixium-vision
Pixium Vision est coté sur Euronext (Compartiment C) à Paris
ISIN: FR0011950641 ; Mnemo: PIX
IRIS® est une marque déposée de Pixium-Vision SA
Les actions Pixium Vision sont éligibles PEA-PME et FCPI

Avertissement :Le présent communiqué contient de manière implicite ou expresse certaines déclarations prospectives relatives à Pixium Vision et à son activité. Ces déclarations dépendent de certains risques connus ou non, d’incertitudes, ainsi que d’autres facteurs, qui pourraient conduire à ce que les résultats réels, les conditions financières, les performances ou réalisations de Pixium Vision diffèrent significativement des résultats, conditions financières, performances ou réalisations exprimés ou sous-entendus dans ces déclarations prospectives.
Pixium Vision émet ce communiqué à la présente date et ne s’engage pas à mettre à jour les déclarations prospectives qui y sont contenues, que ce soit par suite de nouvelles informations, événements futurs ou autres.
Pour une description des risques et incertitudes de nature à entraîner une différence entre les résultats réels, les conditions financières, les performances ou les réalisations de Pixium Vision et ceux contenus dans les déclarations prospectives, veuillez-vous référer au chapitre 4 « Facteurs de risques » du document de référence de la Société enregistré auprès de l’Autorité des marchés financiers sous le numéro R.16-033 le 28 avril 2016, lequel peut être consulté sur les sites de l’Autorité des marchés – AMF (www.amf-france.org) et de Pixium Vision (www.pixium-vision.com).
IRIS® est une marque déposée par Pixium-Vision SA

09/01/2017

Paris, January 5th, 2017. DNA Script, a company focused on the manufacturing of synthetic DNA using a proprietary enzymatic technology, today announced it will present at the Biotech Showcase Conference on Tuesday, January 10th at 5:15 p.m PT in San Francisco, USA. The Biotech Showcase Conference is a financial investor and strategic business partnering event focused on early stage companies in the life science field.

DNA Script manufactures synthetic DNA using a proprietary template-free enzymatic technology. The company technology leverages nature’s most powerful catalysts – enzymes – to overcome current inefficiencies in synthetic DNA production, and enable affordable, rapid, high-quality and high-throughput production of synthetic biology tools, such as oligonucleotides, genes, pathways and genomes. « Our long-term goal is to render DNA and gene synthesis as simple and as affordable as DNA sequencing is today », states Thomas Ybert, President and CEO.

Created in 2014 and based in Paris, France, DNA Script develops its technology in partnership with Institut Pasteur (www.pasteur.fr/en) and Institut Pierre Gilles de Gennes (www.institut-pgg.com). The technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. The company completed its first institutional funding round in May 2016 led by Sofinnova Partners (www.sofinnova.fr) and with participation of Kurma Partners (www.kurmapartners.com/en) and Idinvest Partners (www.idinvest.com/en).

About DNA Script.
DNA Script is a Paris-based company focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script leverages nature’s billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

Its technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. DNA Script develops its technology in partnership with Institut Pasteur and Institut Pierre Gilles de Gennes with the support of key investors such as Sofinnova Partners, Kurma Partners and Idinvest Partners.

www.dnascript.co

Contact
Sylvain Gariel, COO
sg@dnascript.co
+33.6.28.04.53.11
www.dnascript.co